Findings show benefits compared with FOLFIRI for patients with untreated metastatic disease.
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.
Use of injected radioactive beads, with or without bevacizumab, seems to improve survival for patients with metastatic colorectal cancer (mCRC).
At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT).
Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.
Drugs in the Pipeline
Amgen and Allergan announced that their biosimilar candidate ABP 215 met its primary and secondary endpoints in a Phase 3 study evaluating its efficacy and safety compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).
For patients with stage 2-3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival.
Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab
Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT